Welcome to our dedicated page for Clover Health Investments SEC filings (Ticker: CLOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clover Health Investments, Corp. (Nasdaq: CLOV) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as a publicly traded Medicare Advantage and healthcare technology issuer. Clover Health files reports with the U.S. Securities and Exchange Commission that describe its Medicare Advantage insurance operations, technology platform, financial performance, risk factors, and governance.
Investors can review current reports on Form 8-K, where Clover Health announces material events such as quarterly financial results, CMS Star Ratings for its Medicare Advantage PPO and HMO plans, and board or governance changes. Some 8-K filings also reference supplemental written responses to shareholder questions, offering additional context on strategy, cohort economics, and the role of Clover Assistant and Counterpart Health in the business.
In addition to 8-Ks, Clover Health’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the feed) typically provide detailed discussions of its Insurance segment, Medicare Advantage membership trends, non-GAAP measures such as Adjusted EBITDA and Insurance Benefits Expense Ratio, and regulatory considerations related to Medicare, CMS Star Ratings, and value-based care arrangements.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand how items such as Star Rating changes, CMS rate updates, or shifts in membership mix may affect Clover Health’s reported results. Users can also track insider transaction reports on Form 4 when they appear, to monitor equity transactions by directors and officers.
Filings are updated in near real time from the SEC’s EDGAR system, allowing investors, analysts, and other stakeholders to follow Clover Health’s evolving disclosures on Medicare Advantage performance, technology initiatives through Clover Assistant and Counterpart Health, and corporate governance developments.
Clover Health Investments reported strong growth for 2025 but remained unprofitable on a GAAP basis while turning profitable on key non-GAAP metrics and setting targets for 2026 profitability. Full-year 2025 Medicare Advantage membership reached 113,803, up 38%, and total revenues were $1.9 billion, up 40% year-over-year. The company recorded a 2025 GAAP net loss of $86 million, but delivered $22 million of Adjusted EBITDA and $20 million of Adjusted Net Income from continuing operations, indicating an improved underlying earnings profile despite reported losses. Cash, cash equivalents, and investments totaled $319.9 million at year-end, down from $437.6 million a year earlier.
For full-year 2026, Clover Health guides to total revenues between $2.81 billion and $2.92 billion, consolidated gross profit of $470–$510 million, Adjusted EBITDA of $50–$70 million, and GAAP net income between $0 and $20 million, which would mark its first full year of GAAP profitability. Average Medicare Advantage membership is expected to rise to 154,000–158,000, about 46% growth at the midpoint, as the company leans on its Clover Assistant technology and wide-network PPO strategy.
Clover Health Investments General Counsel & Secretary Karen Soares reported a tax-related share disposition. On February 14, 2026, 6,090 shares of Class A common stock were automatically withheld at $2.02 per share to cover tax obligations upon vesting of restricted stock units granted on February 14, 2022. After this withholding, she directly owned 1,204,589 Class A shares.
Clover Health Investments’ Chief Executive Officer and director Andrew Toy reported an automatic share withholding tied to restricted stock unit (RSU) vesting. On February 8, 2026, 85,704 shares of Class A common stock were withheld at $2.13 per share to cover tax obligations arising from the vesting of 6.25% of his original time-based RSU grant from August 8, 2022. After this tax withholding, Toy beneficially owned 9,423,021 shares of Class A common stock directly. The remaining RSUs from the 2022 grant are scheduled to vest quarterly in equal 6.25% installments through August 8, 2026, subject to his continued service.
Clover Health Investments Chief Financial Officer Peter J. Kuipers reported a routine tax-related share withholding. On January 29, 2026, 156,856 shares of Class A Common Stock were automatically withheld at $2.31 per share to cover tax obligations from vesting restricted stock units.
This withholding relates to 6.25% of the original time-based RSU grant awarded on April 29, 2024. After the transaction, Kuipers beneficially owned 5,758,353 Class A shares. The remaining RSUs are scheduled to vest in equal quarterly installments through April 29, 2028, subject to his continued service.
Clover Health Investments CEO Andrew Toy reported an automatic share withholding to cover taxes tied to vesting stock units. On January 15, 2026, 60,764 shares of Class A common stock were withheld at $2.81 per share in connection with the vesting of 6.25% of a restricted stock unit (RSU) grant originally awarded on October 15, 2024.
Following this tax withholding, Toy directly beneficially owned 9,508,725 Class A shares. The remaining RSUs from the October 2024 grant are scheduled to vest quarterly in equal 6.25% installments, with the final vesting date on October 15, 2028, contingent on Toy’s continued service with the company.
Clover Health Investments (CLOV) filed a Form 4 detailing an automatic tax withholding transaction for its General Counsel & Secretary, Karen M. Soares. On January 15, 2026, 11,686 shares of Class A common stock were withheld at $2.81 per share to cover tax obligations arising from the vesting of restricted stock units (RSUs). After this withholding, Soares beneficially owned 1,210,679 shares of Class A common stock in direct ownership form.
The footnote explains that this withholding relates to the vesting of 6.25% of an RSU grant awarded on October 15, 2024. The remaining RSUs from this grant are scheduled to vest quarterly in equal 6.25% installments, with the final vesting date on October 15, 2028, assuming Soares continues in service through each vesting date.
Clover Health Investments, Corp. CEO Conrad Wai reported an automatic share withholding related to restricted stock vesting. On January 15, 2026, 25,868 shares of Class A common stock were withheld at $2.81 per share to cover tax obligations arising from the vesting of 6.25% of a prior RSU grant made on October 15, 2024.
After this tax withholding, Wai beneficially owned 1,025,806 Class A shares directly. In addition, a trust for the benefit of his family, of which he is a co‑trustee, held 1,610,482 Class A shares indirectly. The remaining RSUs from the 2024 grant are scheduled to vest quarterly in equal 6.25% installments through October 15, 2028, subject to his continued service.
Clover Health Investments, Corp. reported insider transactions by CEO, Medicare Advantage Jamie L. Reynoso in Class A Common Stock. On January 15, 2026, 14,732 shares were automatically withheld at $2.81 per share to cover tax obligations tied to the vesting of 6.25% of previously granted RSUs, which continue to vest quarterly at 6.25% through October 15, 2028, subject to continued service.
On January 20, 2026, Reynoso sold 4,597 shares at a weighted average price of $2.58 per share under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2025. Following these transactions, she directly owns 2,737,700 shares of Class A Common Stock.
Clover Health Investments executive Brady Patrick Priest, CEO of Home Care, reported routine share withholding to cover taxes on vested RSUs. On January 15, 2026, 18,076 shares of Class A common stock at $2.81 per share were automatically withheld to satisfy tax obligations tied to the vesting of 6.25% of RSUs granted on October 15, 2024, leaving 2,210,507 shares beneficially owned directly. On January 18, 2026, an additional 36,923 shares at $2.54 per share were withheld for taxes on another 6.25% RSU vesting from a July 18, 2022 grant, after which Priest directly beneficially owned 2,173,584 shares of Class A common stock.
Clover Health (CLOV) insider Jamie Reynoso has filed a notice to sell common stock under Rule 144. The notice covers 4,597 common shares to be sold through Morgan Stanley Smith Barney LLC on or around 01/20/2026 on the NASDAQ market, with an indicated aggregate market value of 11,676.38. These 4,597 shares were acquired as restricted stock units from the issuer on 01/15/2026.
The notice also lists prior sales of Clover Health common stock for the same account during the past three months, including 2,102 shares sold on 01/07/2026 for gross proceeds of 5,319.32, 4,913 shares sold on 12/18/2025 for 12,813.60, and 30,385 shares sold on 11/04/2025 for 108,854.26. The filing reports that 424,304,898 shares of the issuer’s common stock were outstanding at the time referenced in the notice.